Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Obinutuzumab and venetoclax with fixed-duration versus MRD-guided venetoclax maintenance in first-line unfit CLL
NL-OMON23205Phase 2Recruiting
- Sponsor
- HOVON
- Start
- Dec 2016
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of obinutuzumab and venetoclax in chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) (2 arms), sponsored by HOVON. Primary endpoint: Primary efficacy endpoint. Started Dec 2016; status: recruiting.
02
Drugs
obinutuzumabvenetoclax
03
Conditions
chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)
Beyond the preview
Go deeper on NL-OMON23205.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON23205.